首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2020年 1期 “肝胆胰疾病的中西医结合治疗” => 专家论坛 =>原发性胆汁性胆管炎的..
原发性胆汁性胆管炎的熊去氧胆酸生化应答预测及中西医结合治疗
Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis
文章发布日期:2019年12月20日  来源:  作者:王晓静,刘尧,王宪波  点击次数:155次  下载次数:52次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:原发性胆汁性胆管炎(PBC)是免疫介导的慢性进展性的肝内胆汁淤积性疾病,熊去氧胆酸(UDCA)的治疗可明显改善PBC患者的预后,但仍存在一定的UDCA应答不佳的人群,是目前导致疾病进展的主要危险因素。多个基于生化应答的评估模型及评分系统已应用于临床用于筛选应答不佳者。中西医结合治疗PBC在临床上显示了很好的前景,在改善PBC患者症状、肝脏生化及纤维化指标,提高生化应答率等方面有一定优势,但在临床研究设计、疗效判定等方面尚需要进一步完善。
【Abstract】:Primary biliary cholangitis (PBC) is an immune-mediated chronic and progressive intrahepatic cholestasis disease. Treatment with ursodeoxycholic acid (UDCA) can significantly improve the prognosis of patients with PBC, but some patients still have poor response to UDCA, which is the main risk factor for disease progression. Several evaluation models and scoring systems based on biochemical response have been applied to screen out patients with poor response in clinical practice. Integrated traditional Chinese and Western medicine therapy for PBC has certain advantages in improving the symptoms, liver biochemistry, fibrosis indices, and biochemical response rate of PBC patients and thus holds promise for clinical application; however, further improvement is needed for experimental design and efficacy evaluation.
【关键字】:原发性胆汁性胆管炎; 生化学应答; 中西医结合疗法
【Key words】:primary biliary cholangitis; biochemical response; TCM WM therapy
【引证本文】:WANG XJ, LIU Y, WANG XB. Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis[J]. J Clin Hepatol, 2020, 36(1): 26-30. (in Chinese)
王晓静, 刘尧, 王宪波. 原发性胆汁性胆管炎的熊去氧胆酸生化应答预测及中西医结合治疗[J]. 临床肝胆病杂志, 2020, 36(1): 26-30.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号